We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Automated Phone Speech Test Identifies Alzheimer’s Pathology for Prescreening

By HospiMedica International staff writers
Posted on 22 May 2026

Alzheimer’s disease assessment and trial recruitment often rely on costly, invasive biomarker testing and clinic-based cognitive evaluations, limiting scalability as populations age. More...

Providers and trial sponsors need remote tools that can help triage candidates and monitor cognition without requiring in-person visits. A new automated, phone-based speech biomarker now offers a scalable approach for detecting cognitive impairment and signals of underlying Alzheimer’s pathology across multiple languages.

ki:elements’ (Saarbrücken, Germany) Speech Biomarker for Cognition (SB-C) was evaluated in peer-reviewed research conducted with the PROSPECT-AD consortium. The assessment is delivered via the Mili platform, which places a phone call to participants at home and administers a 10-minute task through an AI voice agent. The study enrolled 736 participants across five independent cohorts in Spain, the UK, Germany, and Sweden.

SB-C analyzes 70 distinct speech features to index cognitive efficiency and generate an automatic biomarker score. The approach distinguished cognitively unimpaired individuals from those with mild cognitive impairment (MCI) or early dementia and classified cerebrospinal fluid biomarker status remotely. Performance included identification of amyloid-beta positivity with an AUC of up to 0.74 and phosphorylated tau 181 positivity with an AUC of up to 0.82.

The tool showed multilingual sensitivity across Spanish, Catalan, German, English, and Swedish. It demonstrated strong convergent validity with established measures such as MMSE and PACC-5 and is validated following the Digital Medicine Society’s V3 Framework. It is currently deployed as a pre-screening tool in multiple Alzheimer’s disease clinical trials to enrich for biomarker‑positive participants prior to invasive testing.

“This study gives us real-world, multi-site evidence that a speech assessment can track with established cognitive measures and distinguish patients by their underlying pathology. For sponsors, this translates directly into faster, smarter recruitment, and a lower-burden tool for participants,” said Dr. Alexandra König, Chief Clinical Research Officer of ki:elements and corresponding author of the study.

Related Links
ki:elements


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Vessel Sealing Instrument
ERGOseal
New
Radiofrequency Generator
GX1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Even though the team’s new bioelectronic is only about the size of a fingertip, it could offer an effective and biocompatible approach to addressing high blood pressure (photo courtesy of Tao Zhou/Penn State)

Stretchable Bioelectronic Implant Lowers Blood Pressure in Preclinical Study

Hypertension, or high blood pressure, drives major cardiovascular morbidity and affects nearly half of adults in the United States. About one in ten patients develop drug‑resistant hypertension that persists... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.